$5M Award Accelerates Alzheimer's Immune Therapy Research

Scientists are racing toward a new frontier in Alzheimer's treatment, and they just got a major boost to cross the finish line faster.

MindImmune, a Cambridge-based biotech company, received a $5 million award from the Alzheimer's Drug Discovery Foundation to accelerate development of MITI-101. This first-in-class therapy takes a completely different approach than existing treatments by targeting the immune system's role in brain degeneration.

For years, Alzheimer's research focused almost exclusively on clearing toxic protein buildup in the brain. But mounting evidence shows that chronic inflammation and immune dysfunction may actually drive the disease long before symptoms appear, sometimes decades earlier.

MITI-101 works upstream of the damage by modulating immune cell function to reduce sustained neuroinflammatory harm. Instead of just addressing the aftermath, this therapy aims to interrupt a fundamental process that fuels neurodegeneration from the start.

"This support from the ADDF empowers us to push the boundaries of immune biology in neurodegeneration," said Stevin Zorn, MindImmune's Chief Science Officer. The company plans to complete critical translational studies and prepare for FDA submission to begin early clinical trials.

The Ripple Effect

This investment signals a major shift in how the medical community approaches Alzheimer's treatment. Dr. Howard Fillit, Chief Science Officer of the ADDF, called immune-focused strategies "essential to a broader precision medicine framework" for effectively treating and ultimately preventing the disease.

The ADDF has funded nearly 800 Alzheimer's programs across 21 countries since 1998, contributing to breakthroughs like the first Alzheimer's PET scan and blood test. Their backing of MindImmune reflects growing confidence that targeting neuroinflammation could unlock treatments that actually alter disease progression rather than just managing symptoms.

With over 55 million people worldwide living with dementia, and that number expected to nearly triple by 2050, new approaches can't come fast enough. Families who've watched loved ones slip away know that incremental improvements aren't enough.

This therapy represents hope that scientists are finally addressing what may be the true culprit behind one of medicine's most devastating diseases.